From: Metabolic phenotypes in primary unknown metastatic carcinoma
Clinicopathologic parameters | No. of patients (n = 59*) (%) | Overall survival | |||
---|---|---|---|---|---|
No. of cases | Patient death | Â | Median survival (95% CI) (months) | P -value | |
Glut-1 (T) | Â | Â | Â | Â | 0.101 |
 Negative | 34 | 13 |  | 74 (49–98) |  |
 Positive | 25 | 5 |  | 55 (42–68) |  |
Glut-1 (S) | Â | Â | N/A | Â | N/A |
 Negative | 59 | 18 |  | 84 (66–102) |  |
 Positive | 0 | 0 |  | N/A |  |
CAIX (T) | Â | Â | Â | Â | 0.272 |
 Negative | 51 | 17 |  | 82 (63–101) |  |
 Positive | 8 | 1 |  | 54 (30–79) |  |
CAIX (S) | Â | Â | Â | Â | N/A |
 Negative | 57 | 18 |  | N/A |  |
 Positive | 2 | 0 |  | N/A |  |
MCT4 (T) | Â | Â | Â | Â | 0.759 |
 Negative | 19 | 5 |  | 87 (59–115) |  |
 Positive | 40 | 13 |  | 80 (57–103) |  |
MCT4 (S) | Â | Â | Â | Â | 0.631 |
 Negative | 34 | 9 |  | 94 (73–115) |  |
 Positive | 25 | 9 |  | 43 (29–57) |  |
GLS1 (T) | Â | Â | Â | Â | 0.139 |
 Negative | 39 | 10 |  | 49 (38–60) |  |
 Positive | 20 | 8 |  | 73 (42–103) |  |
GLS1 (S) | Â | Â | Â | Â | 0.721 |
 Negative | 50 | 15 |  | 84 (65–104) |  |
 Positive | 9 | 3 |  | 46 (22–69) |  |
GDH (T) | Â | Â | Â | Â | 1.000 |
 Negative | 7 | 2 |  | 28 (14–39) |  |
 Positive | 52 | 16 |  | 85 (66–104) |  |
GDH (S) | Â | Â | Â | Â | 0.786 |
 Negative | 44 | 13 |  | 90 (72–109) |  |
 Positive | 15 | 5 |  | 40 (19–60) |  |
ASCT2 (T) | Â | Â | Â | Â | 0.506 |
 Negative | 38 | 13 |  | 78 (54–101) |  |
 Positive | 21 | 5 |  | 36 (27–45) |  |
ASCT2 (S) | Â | Â | Â | Â | 0.227 |
 Negative | 56 | 16 |  | 87 (68–105) |  |
 Positive | 3 | 2 |  | 16 (1–32) |  |
ATP synthase (T) | Â | Â | Â | Â | 0.653 |
 Negative | 2 | 1 |  | 10 (10–10) |  |
 Positive | 57 | 17 |  | 85 (67–104) |  |
ATP synthase (S) | Â | Â | Â | Â | 0.535 |
 Negative | 48 | 14 |  | 88 (68–107) |  |
 Positive | 11 | 4 |  | 23 (12–34) |  |
SDHA (T) | Â | Â | Â | Â | 0.906 |
 Negative | 3 | 1 |  | 28 (13–43) |  |
 Positive | 56 | 17 |  | 84 (66–103) |  |
SDHA (S) | Â | Â | Â | Â | 0.588 |
 Negative | 44 | 13 |  | 90 (70–109) |  |
 Positive | 15 | 5 |  | 37 (15–58) |  |
SDHB (T) | Â | Â | Â | Â | 0.166 |
 Negative | 23 | 5 |  | 86 (56–115) |  |
 Positive | 36 | 13 |  | 79 (57–102) |  |
SDHB (S) | Â | Â | Â | Â | 0.923 |
 Negative | 51 | 16 |  | 84 (65–103) |  |
 Positive | 8 | 2 |  | 27 (16–37) |  |